Acciones Isodiol International Inc. Canadian Securities Exchange
Acciones
ISOL
CA46500L2003
Farmacéuticos
Ventas 2018 | 19,14 M 26,31 M 17,71 M | Ventas 2019 | 22,25 M 30,59 M 20,59 M | Capitalización | 49,96 M 68,68 M 46,23 M |
---|---|---|---|---|---|
Resultado Neto 2018 | -36 M -49,49 M -33,31 M | Resultado Neto 2019 | -126 M -173 M -117 M | VE / Ventas 2018 | 12,6 x |
Posición de caja neta 2018 | 15,55 M 21,38 M 14,39 M | Deuda neta 2019 | 5,22 M 7,18 M 4,83 M | VE / Ventas 2019 | 2,48 x |
P/E ratio 2018 |
-4,94
x | P/E ratio 2019 |
-0,37
x | Empleados | - |
Rendimiento 2018 * |
-
| Rendimiento 2019 |
-
| Flotante | 100 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 14/02/19 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/05/17 |
Director/Board Member | - | 30/08/18 | |
Director/Board Member | - | 21/11/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+41,52 % | 6204,31 M | |
-23,06 % | 4093,23 M | |
+9,36 % | 3477,34 M | |
-19,39 % | 2818,85 M | |
-11,05 % | 2275,7 M | |
+45,24 % | 1938,18 M | |
+48,41 % | 1531,55 M | |
-8,31 % | 1508,95 M | |
-18,04 % | 1474,24 M |